Comparative 3 Year ACTIS™ Stem data



ACTIS™
Total Hip System

Survival analysis for all-cause revision following primary total hip arthroplasty (THA) with a medial collared, triple-tapered primary hip stem versus other implants in real-world settings.

Chitnis A, Mantel J, Ruppenkamp J, Bourcet A, Holy C
Current Medical Research and Opinion 2020 vol 36 no 11 1839-1845

- A retrospective cohort study identified 1,213 patients who received the ACTIS™ Total Hip. This group was compared to 6,916 patients who received other THA implants.
- Data was drawn from the Mercy Healthcare Systems Orthopedics Database, a large US based multi-state database.
- Kaplan-Meier survival curves were generated, and a multivariable Cox proportional hazard model was used to compare the relative risk of revision.

57% lower risk of revisions
Adjusted Hazard Ratio 0.43 ((0.19-0.97)p=0.042



57% Reduced Risk of Revision when Compared to Other THA Implants

Please refer to the instructions for use for a complete list of indications, contraindications, warnings and precautions.

DePuy Synthes
THE ORTHOPAEDICS COMPANY OF Johnson & Johnson

Johnson & Johnson Medical Limited. Baird House, 4 Lower Gilmore Bank, Edinburgh, EH3 9QP, United Kingdom.
Incorporated and registered in Scotland under company number SC132162.
depuysynthes.com

© DePuy Synthes 2022. All rights reserved.
155950-221115 DSUS/EMEA